Literature DB >> 21833065

Experimental therapies for Parkinson's disease: Why fake it?

Alla Katsnelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21833065     DOI： 10.1038/476142a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  15 in total

1.  Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers.

Authors:  Scott Y H Kim; Samuel Frank; Robert Holloway; Carol Zimmerman; Renee Wilson; Karl Kieburtz
Journal:  Arch Neurol       Date:  2005-09

2.  Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  Robert E Gross; Raymond L Watts; Robert A Hauser; Roy Ae Bakay; Heinz Reichmann; Rüdiger von Kummer; William G Ondo; Elke Reissig; Wilhelm Eisner; Heike Steiner-Schulze; Harald Siedentop; Klaus Fichte; Walter Hong; Michael Cornfeldt; Katherine Beebe; Rupert Sandbrink
Journal:  Lancet Neurol       Date:  2011-05-10       Impact factor: 44.182

3.  Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants.

Authors:  Marios Politis; Kit Wu; Clare Loane; Niall P Quinn; David J Brooks; Stig Rehncrona; Anders Bjorklund; Olle Lindvall; Paola Piccini
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

4.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Authors:  Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

5.  Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.

Authors:  Steven S Gill; Nikunj K Patel; Gary R Hotton; Karen O'Sullivan; Renée McCarter; Martin Bunnage; David J Brooks; Clive N Svendsen; Peter Heywood
Journal:  Nat Med       Date:  2003-03-31       Impact factor: 53.440

6.  Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial.

Authors:  Cynthia McRae; Eva Cherin; T Gayle Yamazaki; Gretchen Diem; Alexander H Vo; Dan Russell; J Heiner Ellgring; Stanley Fahn; Paul Greene; Sandra Dillon; Hal Winfield; Kimberly B Bjugstad; Curt R Freed
Journal:  Arch Gen Psychiatry       Date:  2004-04

7.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Authors:  Michael G Kaplitt; Andrew Feigin; Chengke Tang; Helen L Fitzsimons; Paul Mattis; Patricia A Lawlor; Ross J Bland; Deborah Young; Kristin Strybing; David Eidelberg; Matthew J During
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

Review 8.  Spheramine for treatment of Parkinson's disease.

Authors:  Natividad P Stover; Ray L Watts
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

9.  A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Authors:  C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

10.  Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Authors:  Anthony E Lang; Steven Gill; Nik K Patel; Andres Lozano; John G Nutt; Richard Penn; David J Brooks; Gary Hotton; Elena Moro; Peter Heywood; Matthew A Brodsky; Kim Burchiel; Patrick Kelly; Arif Dalvi; Burton Scott; Mark Stacy; Dennis Turner; V G Frederich Wooten; William J Elias; Edward R Laws; Vijay Dhawan; A Jon Stoessl; James Matcham; Robert J Coffey; Michael Traub
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422
View more
  5 in total

1.  Differential behavioral outcomes following neonatal versus fetal human retinal pigment epithelial cell striatal implants in parkinsonian rats.

Authors:  Kaspar Russ; Joseph Flores; Tomasz Brudek; Doris J Doudet
Journal:  J Neural Transm (Vienna)       Date:  2017-02-04       Impact factor: 3.575

2.  When norepinephrine becomes a driver of breathing irregularities: how intermittent hypoxia fundamentally alters the modulatory response of the respiratory network.

Authors:  Sébastien Zanella; Atsushi Doi; Alfredo J Garcia; Frank Elsen; Sarah Kirsch; Aguan D Wei; Jan-Marino Ramirez
Journal:  J Neurosci       Date:  2014-01-01       Impact factor: 6.167

3.  Network modulation following sham surgery in Parkinson's disease.

Authors:  Ji Hyun Ko; Andrew Feigin; Paul J Mattis; Chris C Tang; Yilong Ma; Vijay Dhawan; Matthew J During; Michael G Kaplitt; David Eidelberg
Journal:  J Clin Invest       Date:  2014-07-18       Impact factor: 14.808

4.  Sham surgery controls in Parkinson's disease clinical trials: views of participants.

Authors:  Scott Y H Kim; Raymond De Vries; Robert G Holloway; Renee Wilson; Sonali Parnami; H Myra Kim; Samuel Frank; Karl Kieburtz
Journal:  Mov Disord       Date:  2012-08-23       Impact factor: 10.338

5.  The potential benefit of the placebo effect in sham-controlled trials: implications for risk-benefit assessments and informed consent.

Authors:  Remy L Brim; Franklin G Miller
Journal:  J Med Ethics       Date:  2012-12-13       Impact factor: 2.903
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.